Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated MilestonesGlobeNewsWire • 01/09/23
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're PerformingInvestors Business Daily • 12/28/22
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous TransplantGlobeNewsWire • 12/10/22
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts - Beam Therapeutics (NASDAQ:BEAM), BioNTech (NASDAQ:BNTX)Benzinga • 12/02/22
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201GlobeNewsWire • 12/02/22
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap ConferenceGlobeNewsWire • 11/30/22
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 11/14/22
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/22
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/07/22
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual MeetingGlobeNewsWire • 11/03/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B InfectionGlobeNewsWire • 09/19/22